Dexmedetomidine inhibits microglial activation through SNHG14/HMGB1 pathway in spinal cord ischemia-reperfusion injury mice

References

• Zhu P, Li J-x, Fujino M, et al. Development and treatments of inflammatory cells and cytokines in spinal cord ischemia-reperfusion injury. Mediators Inflamm. 2013;2013:701970–701970.
   PubMed Web of Science ®Google Scholar
• Bell MT, Puskas F, Agoston VA, et al. Toll-like receptor 4-dependent microglial activation mediates spinal cord ischemia-reperfusion injury. Circulation. 2013;128(11 Suppl 1):S152–S6.
   PubMed Web of Science ®Google Scholar
• Smith PD, Bell MT, Puskas F, et al. Preservation of motor function after spinal cord ischemia and reperfusion injury through microglial inhibition. Ann Thorac Surg. 2013;95(5):1647–1653.
   PubMed Web of Science ®Google Scholar
• Avgousti DC, Herrmann C, Kulej K, et al. A core viral protein binds host nucleosomes to sequester immune danger signals. Nature. 2016;535(7610):173–177.
   PubMed Web of Science ®Google Scholar
• Chen X, Wu S, Chen C, et al. Omega-3 polyunsaturated fatty acid supplementation attenuates microglial-induced inflammation by inhibiting the HMGB1/TLR4/NF-κB pathway following experimental traumatic brain injury. J Neuroinflammation. 2017;14(1):143–143.
   PubMedGoogle Scholar
• Takizawa T, Shibata M, Kayama Y, et al. High-mobility group box 1 is an important mediator of microglial activation induced by cortical spreading depression. J Cereb Blood Flow Metab. 2017;37(3):890–901.
   PubMed Web of Science ®Google Scholar
• Li X-Q, Chen F-S, Tan W-F, et al. Elevated microRNA-129-5p level ameliorates neuroinflammation and blood-spinal cord barrier damage after ischemia-reperfusion by inhibiting HMGB1 and the TLR3-cytokine pathway. J Neuroinflammation. 2017;14(1):205–205.
   PubMedGoogle Scholar
• Zhang J-j, Peng K, Zhang J, et al. Dexmedetomidine preconditioning may attenuate myocardial ischemia/reperfusion injury by down-regulating the HMGB1-TLR4-MyD88-NF-small ka, CyrillicB signaling pathway. PLoS One. 2017;12(2):e0172006.
   PubMed Web of Science ®Google Scholar
• Liu J, et al. Dexmedetomidine preconditioning ameliorates inflammation and blood-spinal cord barrier damage after spinal cord ischemia-reperfusion injury by down-regulation high mobility group box 1-toll-like receptor 4-nuclear factor kappaB signaling pathway. Spine (Phila Pa 1976). 2019;44(2):E74–e81.
   PubMed Web of Science ®Google Scholar
• Liu Z, et al. Long non-coding RNA SNHG14 contributes to gastric cancer development through targeting miR-145/SOX9 axis. J Cell Biochem. 2018;119(8):6905–6913.
   PubMed Web of Science ®Google Scholar
• Jiao P, Hou J, Yao M, et al. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer. Biomed Pharmacother. 2019;117:109164.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Yu C, Qin W. LncRNA SNHG14 promotes inflammatory response induced by cerebral ischemia/reperfusion injury through regulating miR-136-5p /ROCK1. Cancer Gene Ther. 2019;26(7–8):234–247.
   PubMed Web of Science ®Google Scholar
• Qi X, Shao M, Sun H, et al. Long non-coding RNA SNHG14 promotes microglia activation by regulating miR-145-5p/PLA2G4A in cerebral infarction. Neuroscience. 2017;348:98–106.
   PubMed Web of Science ®Google Scholar
• Bell MT, Puskas F, Smith PD, et al. Attenuation of spinal cord ischemia-reperfusion injury by specific alpha-2a receptor activation with dexmedetomidine. J Vasc Surg. 2012;56(5):1398–1402.
   PubMed Web of Science ®Google Scholar
• Basso DM, Fisher LC, Anderson AJ, et al. Basso mouse scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma. 2006;23(5):635–659.
   PubMed Web of Science ®Google Scholar
• Orihuela R, McPherson CA, Harry GJ. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol. 2016;173(4):649–665.
   PubMed Web of Science ®Google Scholar
• Baptista FI, Aveleira CA, Castilho ÁF, et al. Elevated glucose and interleukin-1β differentially affect retinal microglial cell proliferation. Mediators Inflamm. 2017;2017:4316316–4316316.
   PubMed Web of Science ®Google Scholar
• Freeman KA, Fullerton DA, Foley LS, et al. Spinal cord protection via alpha-2 agonist-mediated increase in glial cell-line-derived neurotrophic factor. J Thorac Cardiovasc Surg. 2015;149(2):578–584; discussion 584–6.
   PubMed Web of Science ®Google Scholar
• Ma J, Zhang X-L, Wang C-Y, et al. Dexmedetomidine alleviates the spinal cord ischemia-reperfusion injury through blocking mast cell degranulation. Int J Clin Exp Med. 2015;8(9):14741–14749.
   PubMed Web of Science ®Google Scholar
• Liu Y, Pan L, Jiang A, et al. Hydrogen sulfide upregulated lncRNA CasC7 to reduce neuronal cell apoptosis in spinal cord ischemia-reperfusion injury rat. Biomed Pharmacother. 2018;98:856–862.
   PubMed Web of Science ®Google Scholar
• Jia H, Ma H, Li Z, et al. Downregulation of LncRNA TUG1 inhibited TLR4 signaling pathway-mediated inflammatory damage after spinal cord ischemia reperfusion in rats via suppressing TRIL expression. J Neuropathol Exp Neurol. 2019;78(3):268–282.
   PubMed Web of Science ®Google Scholar
• Lin H-C, Yeh C-C, Chao L-Y, et al. The hypoxia-responsive lncRNA NDRG-OT1 promotes NDRG1 degradation via ubiquitin-mediated proteolysis in breast cancer cells. Oncotarget. 2018;9(12):10470–10482.
   PubMedGoogle Scholar
• Gao D, Lv A-E, Li H-P, et al. LncRNA MALAT-1 Elevates HMGB1 to Promote Autophagy Resulting in Inhibition of Tumor Cell Apoptosis in Multiple Myeloma. J Cell Biochem. 2017;118(10):3341–3348.
   PubMed Web of Science ®Google Scholar
• Coursin DB, Coursin DB, Maccioli GA. Dexmedetomidine. Curr Opin Crit Care. 2001;7(4):221–226.
   PubMedGoogle Scholar